|Bid||13.21 x 1800|
|Ask||0.00 x 800|
|Day's Range||13.10 - 13.26|
|52 Week Range||10.08 - 14.51|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||19.88|
|Forward Dividend & Yield||0.12 (0.92%)|
|1y Target Est||16.21|
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
(Bloomberg Opinion) -- It’s a deal linking Shanghai and Zurich, but the real target looks to be London.China Pacific Insurance (Group) Co. is in talks to invest at least $2 billion in Swiss Re AG, Manuel Baigorri of Bloomberg News reported Wednesday, citing people familiar with the matter. Shanghai-based China Pacific is the country’s third-largest insurer, while Zurich-based Swiss Re is Switzerland’s biggest reinsurance company.At the current market price, $2 billion would buy China Pacific less than 6% of its target. That won’t give the Chinese insurer any sway over how Swiss Re spends its cash — thought to be the motivation for SoftBank Group Corp.’s ultimately abandoned interest in the company last year. As a passive financial investment, a deal would make sense for the acquirer: Swiss Re shares have gained 17% this year, and the reinsurer trades on a chunky 5.3% dividend yield. The real prize for the Chinese company, though, would be the parallel investment that Swiss Re would make in China Pacific.This is where London comes in. China Pacific said in September that it’s planning to sell global depository receipts to be listed in the British capital. This would be only the second listing under the Shanghai-London Stock Connect program. There’s a lot of political capital riding on this endeavor: China Pacific is controlled by the Shanghai government, and an anchor investor such as Swiss Re would boost the profile and attractions of the offering.Huatai Securities Co. became the first company to start trading under the cross-border listing program in June. While the brokerage’s shares have gained more than 20% since their debut, trading volume has been anemic: An average of about 250,000 GDRs out of 735 million outstanding have changed hands daily. Anything that helps to burnish interest in the China Pacific sale will be welcome.Swiss Re said in a statement that it’s been exploring a potential investment in a sale of new securities by China Pacific. The Swiss company would spend $500 million to $1 billion for a minority stake under the deal being discussed, according to the Bloomberg News report.China Pacific has a good story to tell. It’s one of the key players in a market where insurance demand is surging as incomes rise and state-run health and welfare systems remain underdeveloped. The insurer’s net income has climbed by half in the past two years and earnings per share are forecast to grow 60% in 2019, according to the consensus estimate compiled by Bloomberg. The shares have gained 20% in Hong Kong this year.To be sure, there would be other benefits from a tie-up. China Pacific may gain access to the Swiss reinsurer’s product development expertise and a wealth of data that can help in pricing risk. These advantages are gaining in importance as China opens up its already competitive financial markets to further foreign participation.Swiss Re already has interests in the region, via stakes in New China Life Insurance Co. and FWD Group Ltd., the Asian insurer backed by Hong Kong tycoon Richard Li. The company has also held discussions with Chinese authorities about an investment in Beijing-based Anbang Insurance Group Co., Bloomberg New reported last year.Still, after suffering losses from major claims like Hurricane Dorian in the Caribbean and suspending its U.K. insurance IPO, it’s smart for Swiss Re to do more with its China connections. A $1 billion slice of China Pacific’s London offering could buy a lot of goodwill. To contact the author of this story: Nisha Gopalan at email@example.comTo contact the editor responsible for this story: Matthew Brooker at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Nisha Gopalan is a Bloomberg Opinion columnist covering deals and banking. She previously worked for the Wall Street Journal and Dow Jones as an editor and a reporter.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
China Life Insurance, the nation's second-largest insurer, posted an almost threefold increase in profit for the first nine months, as a run-up in stocks bolstered investment gains and premium incomes rose.Net income for the first three quarters jumped 190 per cent from a year ago to 57.7 billion yuan (US$8.2 billion) based on the Chinese accounting standard, the insurer said in an exchange statement. The value of new business, a gauge of future profitability, grew by 20 per cent in the period, it said. China Life did not provide data for the third quarter alone in the report.A turnaround on China's Shanghai Composite Index significantly boosted profits of insurance companies, which are allowed to invest as much as 30 per cent of their assets in equities. The benchmark has risen 18 per cent so far this year, reversing an annual loss of 25 per cent in 2018, as policymakers loosen policies to offset the fallout of the China-US trade war and foreign inflows accelerate.China Life's investment yield was 5.72 per cent in the nine-month period, an increase of 2.31 percentage points from a year earlier, it said in the quarterly report. Premium incomes increased 6.1 per cent from a year ago to 497 billion yuan and the number of sales people rose by 10 per cent, to 1.95 million, it said. China Life looks to new technology to boost insurance sales as interim profit misses forecastsShares of China Life have surged 51 per cent this year in Shanghai and its Hong Kong-traded stock has risen 19 per cent.In July, China eased rules for foreign insurance companies looking to enter the country.China's insurance market is dominated by domestic players despite years of reforms. Foreign insurers have an 8.1 per cent share, a level that would suggest mainland consumers have yet to reap benefits that come with greater market competition, according to Moody's Investors Service.This article originally appeared in the South China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore the SCMP app or visit the SCMP's Facebook and Twitter pages. Copyright © 2019 South China Morning Post Publishers Ltd. All rights reserved. Copyright (c) 2019. South China Morning Post Publishers Ltd. All rights reserved.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
When it comes to diversified tech giant Alibaba (NYSE:BABA), being an investor comes with its share of harassment. Nevertheless, it's time to watch for a capitalist opportunity now that a key battle line has been crossed.Source: zhu difeng / Shutterstock.com For U.S. investors, profiting in Chinese stocks has been more challenging these days. Many large-cap stocks and industry leaders in China ranging from Tencent (OTCMKTS:TCEHY), to China Mobile (NYSE:CHL), China Life Insurance Company (NYSE:LFC) or China Petroleum & Chemical Corporation (NYSE:SNP) have produced lackluster or negative returns in their U.S.-listed American Depository Receipts. And certainly the trade war has been a drag on stock performance.But Alibaba stock has been different. That's not to say it's been easy. Still, the fact is BABA has gained about 23% in 2019. The return is more than the S&P 500's climb of 18% and towers above U.S. tech giant Amazon's (NASDAQ:AMZN) 13% year-to-date increase.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Why is Alibaba Stock Different?So, what is the deal with shares of BABA? Alibaba stock has and continues to defeat investors' fears within this macro-charged environment. Most recently BABA stock toppled Street profit and sales forecasts in mid-August. * 7 Beverage Stocks to Buy Now To be certain, there's always going to be something or someone trying to get investors to back away from buying Alibaba despite its successes. For some that might include recent reports the U.S. is considering delisting Chinese stocks. And that threat can't be entirely ignored. Or maybe fake merchandise sales in the past or allegations of accounting shenanigans have prevented investors from taking action in BABA stock?Okay, so there's plenty of reasons not to buy BABA shares. But obviously those arguments don't include price performance. Most important, Alibaba stock continues to come out on top despite headline warnings and a challenging market for Chinese stocks. Now and with BABA crossing an important battle line on the price chart, it's time to put shares on the radar for a well-timed purchase. BABA Stock Weekly ChartAs noted above, capturing BABA stock's gains of around 23% hasn't been a walk in the park. And as expressed, bad press isn't likely to just disappear. The better news is I also don't believe Alibaba's impressive rally is finished. I see a solid entry for a risk-adjusted purchase of BABA stock.The weekly chart shows that since failing from a breakout attempt to new highs last year, Alibaba stock has established a corrective symmetrical triangle base. It's not perfectly formed with clear-cut pivots to define the pattern, but the essence of this bullish formation is there.Following last week's price action, shares of Alibaba are in position to confirm a bullish engulfing candlestick which puts BABA stock back above the 50% retracement level of the base, as well as the triangle's apex line. With stochastics in a pullback set-up in neutral territory and on the verge of signaling a bullish crossover, the situation looks all the more promising. How to Trade AlibabaI'd recommend buying Alibaba shares above $174.88. This entry waits for the BABA stock price to confirm last week's candlestick and reinforces the bias for continued upside in the bullish triangle pattern. If BABA rallies, a breakout through angular resistance near $185 might be watched for adding shares on strength and before looking to take partial profits in-between $195-$215.For containing downside exposure in Alibaba stock, I'd keep an eye on the weekly stochastics to continue to support the position and set a modified stop-loss beneath $165 for a stronger risk-adjusted exit that offers sufficient evidence off and on the price chart for closing the trade.Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. . For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Beverage Stocks to Buy Now * 10 Groundbreaking Technologies Created by Universities * 5 Semiconductor Stocks Worth Your Time The post Alibaba Stock is a Strong Buy Now -- More Than Ever Before appeared first on InvestorPlace.
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In March 2019, China Life Insurance Company Limited (HKG:2628) released its earnings update. Generally, it seems that...
The Zacks Analyst Blog Highlights: China Life Insurance, JD.com, Qudian, China Southern and Sinopec Shanghai
HONG KONG, Aug. 22, 2019 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628, NYSE: LFC) announces the unaudited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the six months ended 30 June 2019 (the "Reporting Period") prepared under the International Financial Reporting Standards today. As at the end of the Reporting Period, the Company's total assets reached RMB3,479,860 million, an increase of 6.9% from the end of 2018. The Company's embedded value was RMB886,804 million, an increase of 11.5% from the end of 2018.
The Zacks Analyst Blog Highlights: China Life Insurance, Qudian, Hexindai, JD.com and China Eastern Airlines
TORONTO , July 9, 2019 /CNW/ - 22 Capital Corp. (LFC-P.V) ("22 Capital") and Trichome Financial Corp. ("Trichome Financial") are pleased to announce that each of 22 Capital and Trichome Financial have received unanimous approval from their respective shareholders for their announced amalgamation under the provisions of the Business Corporations Act ( Ontario ) that will result in a reverse take-over of 22 Capital by the shareholders of Trichome Financial (the "Transaction"). The Transaction, if completed, will constitute 22 Capital's "Qualifying Transaction" as such term is defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange").
HKSE: 2628) announced today that Mr. Zhao Lijun tendered his resignation as the person in charge of finance (equivalent to Chief Financial Officer) of the Company on July 8, 2019 due to the adjustment of management division, which took effect on the same day. The Company would like to express its gratitude to Mr. Zhao Lijun for his contribution to the Company during his tenure of service as the person in charge of finance of the Company. China Life also announced that the Board has nominated Mr. Zhao Peng as the person in charge of finance of the Company at the twelfth meeting of the sixth session of the Board.
China Life Insurance Company Limited (HKG:2628) saw significant share price movement during recent months on the SEHK...
April 25 (Reuters) - China Life Insurance Co Ltd : * SAYS Q1 PREMIUM UP 11.9 PERCENT Y/Y AT 272.35 BILLION YUAN ($40.40 billion) Source text in Chinese: https://bit.ly/2Vp0aFR Further company coverage: ...